Massimo Broggini attended the faculty of Science of the University of Milan and gained the specialisation in Biochemistry at the Mario Negri Institute, and the PhD degree at the Open University, London, UK.

He worked in the laboratory of Molecular Pharmacology of the National Cancer Institute of Bethesda, Md, in 1986. Since 1991 he has been the head of the Molecular Pharmacology Unit of the Mario Negri Institute and since 1999 he has been the head of the Laboratory of Molecular Pharmacology at the Department of Oncology of the same Institute. He is a member of the "Pharmacology and Molecular Mechanisms Group" of the European Organisation for the Research and Treatment of Cancer (EORTC) and of the American Association for Cancer Research. He is in the Editorial board of the European Journal of Cancer, Frontiers in Cancer Genetics, Frontiers in Molecular Medicine and American Journal of Cancer Research.

Prof Broggini is author of more than 200 articles published in international journals and is serving as reviewer for more than 20 international journals.

His main research activities are the study of the mechanism of action of new anti-cancer agents, the signal transduction pathways in cancer, the molecular determinants of cellular response to anti-cancer treatments and the genetic alterations in cancer.